2.4.0.8015 - Disclosure - Note 10. Subsequent Eventtruefalsefalse1falsefalsefalsec0_From1Apr2013To30Jun2013http://www.sec.gov/CIK0000894237duration2013-04-01T00:00:002013-06-30T00:00:001true1us-gaap_SubsequentEventsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA6896">
<font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b> Note
10.  Subsequent Event</b></font>
</p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; MARGIN: 0pt" id="PARA6898">
<font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant
to a separation and release agreement dated July 1, 2013, Ms.
Cynthia Ansari resigned from the Vision-Sciences, Inc. Board
of Directors. Previously, Ms. Ansari indicated her intention
to resign as the Company’s Chief Executive Officer and
President on April 30, 2013, which was accepted by the Board
of Directors on May 9, 2013. Ms. Ansari’s resignation
from the Board was not due to any disagreement with the
Company or concerns relating to the Company’s
operations, policies or practices. Under the separation and
release agreement, Ms. Ansari is entitled to receive six
months of severance pay and twelve months of medical
benefits, totaling approximately $190, which was recorded in
the quarter ended June 30, 2013. The agreement also provides
for the lapse of restrictions of 25,126 shares of restricted
stock held by Ms. Ansari and the ability to exercise her
vested options to purchase 375,000 shares of common stock, at
an exercise price of $2.22 per share, through July 9,
2014.</font>
</p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; MARGIN: 0pt" id="PARA7181">
<font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant
to a separation and release agreement dated July 1, 2013, Ms.
Cynthia Ansari resigned from the Vision-Sciences, Inc. Board
of Directors. Previously, Ms. Ansari indicated her intention
to resign as the Company’s Chief Executive Officer and
President on April 30, 2013, which was accepted by the Board
of Directors on May 9, 2013. Ms. Ansari’s resignation
from the Board was not due to any disagreement with the
Company or concerns relating to the Company’s
operations, policies or practices. Under the separation and
release agreement, Ms. Ansari is entitled to receive six
months of severance pay and twelve months of medical
benefits, totaling approximately $190, which was recorded in
the quarter ended June 30, 2013. The agreement also provides
for the lapse of restrictions of 25,126 shares of restricted
stock held by Ms. Ansari and the ability to exercise her
vested options to purchase 375,000 shares of common stock, at
an exercise price of $2.22 per share, through July 9,
2014.</font>
</p><br/>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0falseNote 10. Subsequent EventUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.visionsciences.com/role/Note10SubsequentEvent12